SavedAdd your journal

Journals / Viral Hepatitis Journal / 2018 / Cilt: 24 - Sayı: 3

Does Pegylated-Interferon Still Have High Efficacy Treatment Properties Against Chronic Hepatitis B?

Pegile-İnterferon Kronik Hepatit B’de Hala Yüksek Etkili Tedavi Özelliklerine Sahip mi?

Nefise ÖZTOPRAK
Murat SAYAN
Ülkü USER
Figen SARIGÜL YILDIRIM
Pages
90–95
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We aimed in this study to evaluate theeffectiveness of Peg-IFN and potent NAs (entecavir and tenofovirdisoproxil) and to compare cumulative virological and serologicalresponses in Turkish CHB patients treated between 2006 and 2016.Materials and Methods: In this observational retrospective study,we divided a total of 331 patients, who were diagnosed with CHB,into 3 groups: Peg-IFN treatment group (n=62), entecavir treatmentgroup (n=131) and tenofovir disoproxil treatment group (n=138).Results: Virologic response rate in the Peg-IFN treatment group(90%) at 12 months was higher than in the NAs treatment groups(80% for entecavir and 76% for tenofovir disoproxil) (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: Pegylated-interferon (Peg-IFN) alpha 2a/2b andnucleoside and/or nucleotide analogues (NAs) are currently theonly two treatment approaches approved for the chronic hepatitisB (CHB).
📊
Key Findings & Data:To date, few studies have compared Peg-IFN with NAsin the treatment of CHB.
💡
Conclusion & Impact:We aimed in this study to evaluate theeffectiveness of Peg-IFN and potent NAs (entecavir and tenofovirdisoproxil) and to compare cumulative virological and serologicalresponses in Turkish CHB patients treated between 2006 and 2016.Materials and Methods: In this observational retrospective study,we divided a total of 331 patients, who were diagnosed with CHB,into 3 groups: Peg-IFN treatment group (n=62), entecavir treatmentgroup (n=131) and tenofovir disoproxil treatment group (n=138).Results: Virologic response rate in the Peg-IFN treatment group(90%) at 12 months was higher than in the NAs treatment groups(80% for entecavir and 76% for tenofovir disoproxil) (p
🔬Design:Research Article
📍Scope:2006 Verileri
⚙️Variables:Domain Parameters

Abstract

Objectives: Pegylated-interferon (Peg-IFN) alpha 2a/2b andnucleoside and/or nucleotide analogues (NAs) are currently theonly two treatment approaches approved for the chronic hepatitisB (CHB). To date, few studies have compared Peg-IFN with NAsin the treatment of CHB. We aimed in this study to evaluate theeffectiveness of Peg-IFN and potent NAs (entecavir and tenofovirdisoproxil) and to compare cumulative virological and serologicalresponses in Turkish CHB patients treated between 2006 and 2016.Materials and Methods: In this observational retrospective study,we divided a total of 331 patients, who were diagnosed with CHB,into 3 groups: Peg-IFN treatment group (n=62), entecavir treatmentgroup (n=131) and tenofovir disoproxil treatment group (n=138).Results: Virologic response rate in the Peg-IFN treatment group(90%) at 12 months was higher than in the NAs treatment groups(80% for entecavir and 76% for tenofovir disoproxil) (p

Özet

Amaç: Pegile-interferon (Peg-IFN) alfa 2a/2b ve nükleozid ve nükleotid analogları (NA), şu anda kronik hepatit B (KHB) tedavisi için onaylanmış iki tedavi yaklaşımıdır. Bugüne kadar birkaç çalışma Peg-IFN ve NA’lar arasındaki tedavinin etkinliğini karşılaştırmıştır. Bu çalışmada, 2006-2016 yılları arasında Türk KHB hastalarında Peg-IFN ve potent NA’ların (entekavir ve tenofovir disoproksil) kümülatif virolojik ve serolojik yanıtlarını karşılaştırarak etkinliklerini değerlendirmeyi amaçladık. Gereç ve Yöntemler: Retrospektif gözlemsel olan bu çalışmada KHB tanılı total 331 hasta (Peg-IFN tedavi grubu, n=62, entekavir tedavi grubu, n=131 ve tenofovir disoproksil tedavi grubu, n=138) değerlendirildi. Bulgular: Virolojik yanıt oranı Peg-IFN tedavi grubunda 12. ayda (%90), NA tedavi grubundan (entekavir için %80, tenofovir disoproksil için %76) daha yüksekti (p

🔖

Cite This Article

ÖZTOPRAK, N., SAYAN, M., USER, Ü., YILDIRIM, F. S. (2022). Does Pegylated-Interferon Still Have High Efficacy Treatment Properties Against Chronic Hepatitis B?. Viral Hepatitis Journal, Cilt: 24 - Sayı: 3, 90–95. https://ajindex.com/articles/646399

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (7)

  1. Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH; American Association for the Study of Liver Diseases. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63:261-283. European Association for the Study of the Liver. Electronic address: [email protected]; European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370-398.
  2. Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, Chen DS, Chen HL, Chen PJ, Chien RN, Dokmeci AK, Gane E, Hou JL, Jafri W, Jia J, Kim JH, Lai CL, Lee HC, Lim SG, Liu CJ, Locarnini S, Al Mahtab M, Mohamed R, Omata M, Park J, Piratvisuth T, Sharma BC, Sollano J, Wang FS, Wei L, Yuen MF, Zheng SS, Kao JH. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10:1-98.
  3. LoLok AS, McMahon BJ, Brown RS Jr, Wong JB, Ahmed AT, Farah W, Almasri J, Alahdab F, Benkhadra K, Mouchli MA, Singh S, Mohamed EA, Abu Dabrh AM, Prokop LJ, Wang Z, Murad MH5, Mohammed K. Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis. Hepatology. 2016;63:284-306.
  4. Lucifora J, Protzer U. Attacking hepatitis B virus cccDNA–the holygrail to hepatitis B cure. J Hepatol. 2016;64(Suppl 1):S41-S48. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. Geneva: World Health Organization; 2015 Mar. Executive Summary. Available from: https://www.ncbi. nlm.nih.gov/books/NBK305541/ Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH; American Association for the Study of Liver Diseases. AASLD guidelenes for treatment of chronic hepatitis B. Hepatology. 2016;63:261-283.
  5. Brown RS Jr, McMahon BJ, Lok AS, Wong JB, Ahmed AT, Mouchli MA, Wang Z, Prokop LJ, Murad MH, Mohammed K. Antiviral therapy in chronic hepatitis B viral infection during pregnancy: A systemic review and meta-analysis. Hepatology. 2016;63:319-333.
  6. Kim V, Abreu RM, Nakagawa DM, Baldassare RM, Carrilho FJ, Ono SK. Pegylated interferon alfa for chronic hepatitis B: systematic review and meta-analysis. J Viral Hepat. 2016;23:154-169.
  7. Toy M, Önder FO, Wörmann T, Bozdayi AM, Schalm SW, Borsboom GJ, van Rosmalen J, Richardus JH, Yurdaydin C. Age- and region- specific hepatitis B prevalence in Turkey estimated using generalized linear mixed models: a systematic review. BMC Infect Dis. 2011;11:337. Mese S, Nergiz S, Tekes S, Gul K